Comparison of PillCamCOLON (C2) Capsule and Standard Endoscopy for the Evaluation of Patients With Ulcerative Colitis

For each patient, the study will be conducted in accordance with the following schedule: Information/inclusion visit: D-30 (± 30 days) * Full information about the trial * Verification of inclusion and non-inclusion criteria * Acquisition of informed consent (either the same day or after a period of reflexion) * Medical and surgical history * Clinical examination Endoscopic visit: D0 On two consecutive days or within a maximum of seven days but obligatorily before the anti-Tumor Necrosis Factor (TNF) alpha treatment * Faecal sample (calprotectin) * Clinical examination * Endoscopic examination by PillCamCOLON (C2) then by conventional endoscopy (colonoscopy) -The endoscopic examinations will each be analyzed by a different endoscopist working in a blinded evaluation. An UC activity score will be calculated depending on two scores: MAYO and UCEIS. * Notification of Adverse Event (AE) / Serious Adverse Event (SAE) Follow-up visit: W12 (12 weeks ± 5 days after D0) * Faecal sample (calprotectin) * Clinical examination * Endoscopic examination by PillCamCOLON (C2) then by conventional endoscopy (coloscopy) -The endoscopic examinations will each be analyzed by a different endoscopist working in a blinded evaluation. An UC activity score will be evaluated depending on two scores: MAYO and UCEIS. * Notification of AE/SAE End-of-study visit (possibly by telephone) W14 (± 5 days) \*Notification of AE/SAE